Related Experiment Video
Updated: Nov 7, 2025
04:40
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
2.8K
Rivaroxaban for cancer-associated venous thromboembolism
Bo Liang1, Yi Liang2, Li-Zhi Zhao3
1Nanjing University of Chinese Medicine, Nanjing, China.
Science Progress
|April 29, 2021
Summary
Rivaroxaban shows comparable efficacy and safety to other anticoagulants for cancer-associated venous thromboembolism (VTE). This systematic review found no significant differences in VTE recurrence, bleeding events, or mortality, supporting its use in this patient group.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Cancer patients have an elevated risk of venous thromboembolism (VTE).
- Anticoagulants are the standard treatment for cancer-associated VTE.
- The efficacy and safety of newer oral anticoagulants like rivaroxaban require evaluation.
Purpose of the Study:
- To conduct a systematic review and meta-analysis.
- To evaluate the efficacy and safety of rivaroxaban in cancer patients with VTE.
- To compare rivaroxaban against other anticoagulants for VTE treatment.
Main Methods:
- Systematic literature search of PubMed, Cochrane, Web of Science, and CNKI up to September 2019.
- Inclusion of four trials with 1996 patients.
- Primary outcome: VTE recurrence. Secondary outcomes: bleeding events and all-cause mortality. Data analyzed using risk ratios (RR) and 95% confidence intervals (CI).
Main Results:
- Rivaroxaban demonstrated a non-significant reduction in VTE recurrence (RR=0.68, 95% CI=0.43-1.07).
- No significant differences were observed in major bleeding events (RR=0.86, 95% CI=0.37-2.00), non-major bleeding (RR=1.24, 95% CI=0.73-2.12), or all-cause mortality (RR=0.76, 95% CI=0.40-1.44).
Conclusions:
- Rivaroxaban is as effective and safe as other anticoagulants in cancer patients with VTE.
- Further well-designed randomized controlled trials are needed to confirm these findings.
- Rivaroxaban represents a viable treatment option for cancer-associated VTE.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
90
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
90
01:30Venous Thrombosis IV: Nursing Management
67
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
67
01:30Venous Thrombosis I: Introduction
103
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
103
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.7K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.7K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
90
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
90